Thalidomide and rituximab in Waldenstrom macroglobulinemia

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, Anderson, Kenneth C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2008
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597120/
https://ncbi.nlm.nih.gov/pubmed/18713945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-150854
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge